Benzinga's Top #PreMarket Losers

Orexigen Therapeutics, Inc. OREX fell 10.62 percent to $5.30 in pre-market trading. The company terminated a cardiovascular outcomes trial of its anti-obesity drug Contravene, from which interim results were inadvertently released earlier this year. The trial is not being terminated because of a finding of superiority or harm. An additional trial is expected to be completed in 2020. Star Bulk Carriers Corp. SBLK slipped 7.16 percent to $3.50 in pre-market trading after the company announced a $150.0 million public offering of common shares. Vivint Solar Inc VSLR shares fell 7.15 percent to $13.90 in pre-market trading after the company reported financial results for the first quarter ended March 31, 2015 and issued a forecast for the second quarter. The company's non-GAAP loss before non-controlling interests and redeemable non-controlling interests came in at $0.57 per share for the latest quarter. Macy's, Inc. M shares dropped 2.65 percent to $63.60 in pre-market after the company reported downbeat Q1 earnings. AES Corp AES shares declined 2.26 percent to $13.40 in pre-market trading after the company announced the pricing of a 60 million share offering.